Kazia Therapeutics Limited
As of Oct 22, 2026, Kazia Therapeutics is in Stage 3, the topping phase, now in week 6 (since Sep 14, 2026). It closed at $8.07, 52.2% below its 52-week high and below its 200-day average, which is falling.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is KZIA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
KZIA among Biotechnology147th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …147 | KZIA | Stage 3 · wk 6 | 66 | −15.9% |
Kazia Therapeutics: quick answers
What stage is Kazia Therapeutics in?
As of Oct 22, 2026, Kazia Therapeutics (KZIA) is in Stage 3, the topping phase. It entered Stage 3 on Sep 14, 2026 and is in week 6. What the four stages mean
Is Kazia Therapeutics in an uptrend?
Its uptrend has stalled. Kazia Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 23.1% below its 200-day average, which is falling.
How far is Kazia Therapeutics from its 52-week high?
Kazia Therapeutics closed at $8.07 on Oct 22, 2026, 52.2% below its 52-week high of $16.90. Its 52-week low is $5.00.
How has Kazia Therapeutics performed over the past year?
As of Oct 22, 2026, Kazia Therapeutics is up 14.8% over the past year and up 61.4% so far in 2026.
Which sector and industry is Kazia Therapeutics in?
Kazia Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.